211 related articles for article (PubMed ID: 27049467)
1. Aberrant hnRNP K expression: All roads lead to cancer.
Gallardo M; Hornbaker MJ; Zhang X; Hu P; Bueso-Ramos C; Post SM
Cell Cycle; 2016 Jun; 15(12):1552-7. PubMed ID: 27049467
[TBL] [Abstract][Full Text] [Related]
2. hnRNP K: an HDM2 target and transcriptional coactivator of p53 in response to DNA damage.
Moumen A; Masterson P; O'Connor MJ; Jackson SP
Cell; 2005 Dec; 123(6):1065-78. PubMed ID: 16360036
[TBL] [Abstract][Full Text] [Related]
3. Expression levels of hnRNP K and p21WAF1/CIP1 are associated with resistance to radiochemotherapy independent of p53 pathway activation in rectal adenocarcinoma.
Daskalaki W; Wardelmann E; Port M; Stock K; Steinestel J; Huss S; Sperveslage J; Steinestel K; Eder S
Int J Mol Med; 2018 Dec; 42(6):3269-3277. PubMed ID: 30272263
[TBL] [Abstract][Full Text] [Related]
4. Role of heterogeneous nuclear ribonucleoprotein K in tumor development.
Chen Y; Zeng Y; Xiao Z; Chen S; Li Y; Zou J; Zeng X
J Cell Biochem; 2019 Sep; 120(9):14296-14305. PubMed ID: 31127648
[TBL] [Abstract][Full Text] [Related]
5. Insight into the mechanism of AML del(9q) progression: hnRNP K targets the myeloid master regulators CEBPA (C/EBPα) and SPI1 (PU.1).
Rahn K; Abdallah AT; Gan L; Herbrich S; Sonntag R; Benitez O; Malaney P; Zhang X; Rodriguez AG; Brottem J; Marx G; Brümmendorf TH; Ostareck DH; Ostareck-Lederer A; Crysandt M; Post SM; Naarmann-de Vries IS
Biochim Biophys Acta Gene Regul Mech; 2024 Mar; 1867(1):195004. PubMed ID: 38008244
[TBL] [Abstract][Full Text] [Related]
6. Increased expression of the heterogeneous nuclear ribonucleoprotein K in pancreatic cancer and its association with the mutant p53.
Zhou R; Shanas R; Nelson MA; Bhattacharyya A; Shi J
Int J Cancer; 2010 Jan; 126(2):395-404. PubMed ID: 19609950
[TBL] [Abstract][Full Text] [Related]
7. Bortezomib inhibits Burkitt's lymphoma cell proliferation by downregulating sumoylated hnRNP K and c-Myc expression.
Suk FM; Lin SY; Lin RJ; Hsine YH; Liao YJ; Fang SU; Liang YC
Oncotarget; 2015 Sep; 6(28):25988-6001. PubMed ID: 26317903
[TBL] [Abstract][Full Text] [Related]
8. Uncovering the Role of RNA-Binding Protein hnRNP K in B-Cell Lymphomas.
Gallardo M; Malaney P; Aitken MJL; Zhang X; Link TM; Shah V; Alybayev S; Wu MH; Pageon LR; Ma H; Jacamo R; Yu L; Xu-Monette ZY; Steinman H; Lee HJ; Sarbassov D; Rapado I; Barton MC; Martinez-Lopez J; Bueso-Ramos C; Young KH; Post SM
J Natl Cancer Inst; 2020 Jan; 112(1):95-106. PubMed ID: 31077320
[TBL] [Abstract][Full Text] [Related]
9. MDM2-dependent downregulation of p21 and hnRNP K provides a switch between apoptosis and growth arrest induced by pharmacologically activated p53.
Enge M; Bao W; Hedström E; Jackson SP; Moumen A; Selivanova G
Cancer Cell; 2009 Mar; 15(3):171-83. PubMed ID: 19249676
[TBL] [Abstract][Full Text] [Related]
10. Combined loss of PUMA and p21 accelerates c-MYC-driven lymphoma development considerably less than loss of one allele of p53.
Valente LJ; Grabow S; Vandenberg CJ; Strasser A; Janic A
Oncogene; 2016 Jul; 35(29):3866-71. PubMed ID: 26640149
[TBL] [Abstract][Full Text] [Related]
11. The Eµ-hnRNP K Murine Model of Lymphoma: Novel Insights into the Role of hnRNP K in B-Cell Malignancies.
Malaney P; Velasco-Estevez M; Aguilar-Garrido P; Aitken MJL; Chan LE; Zhang X; Post SM; Gallardo M
Front Immunol; 2021; 12():634584. PubMed ID: 33912162
[TBL] [Abstract][Full Text] [Related]
12. Syntheses and evaluation of new Quinoline derivatives for inhibition of hnRNP K in regulating oncogene c-myc transcription.
Shu B; Zeng P; Kang S; Li PH; Hu D; Kuang G; Cao J; Li X; Zhang M; An LK; Huang ZS; Li D
Bioorg Chem; 2019 Apr; 85():1-17. PubMed ID: 30599408
[TBL] [Abstract][Full Text] [Related]
13. Emerging roles of heterogeneous nuclear ribonucleoprotein K (hnRNP K) in cancer progression.
Barboro P; Ferrari N; Balbi C
Cancer Lett; 2014 Oct; 352(2):152-9. PubMed ID: 25016060
[TBL] [Abstract][Full Text] [Related]
14. Arginine methylation of hnRNP K enhances p53 transcriptional activity.
Chen Y; Zhou X; Liu N; Wang C; Zhang L; Mo W; Hu G
FEBS Lett; 2008 May; 582(12):1761-5. PubMed ID: 18472002
[TBL] [Abstract][Full Text] [Related]
15. hnRNP K suppresses apoptosis independent of p53 status by maintaining high levels of endogenous caspase inhibitors.
Xiao Z; Ko HL; Goh EH; Wang B; Ren EC
Carcinogenesis; 2013 Jul; 34(7):1458-67. PubMed ID: 23455382
[TBL] [Abstract][Full Text] [Related]
16. Protein kinase C-delta mediates down-regulation of heterogeneous nuclear ribonucleoprotein K protein: involvement in apoptosis induction.
Gao FH; Wu YL; Zhao M; Liu CX; Wang LS; Chen GQ
Exp Cell Res; 2009 Nov; 315(19):3250-8. PubMed ID: 19747914
[TBL] [Abstract][Full Text] [Related]
17. hnRNP K Is a Haploinsufficient Tumor Suppressor that Regulates Proliferation and Differentiation Programs in Hematologic Malignancies.
Gallardo M; Lee HJ; Zhang X; Bueso-Ramos C; Pageon LR; McArthur M; Multani A; Nazha A; Manshouri T; Parker-Thornburg J; Rapado I; Quintas-Cardama A; Kornblau SM; Martinez-Lopez J; Post SM
Cancer Cell; 2015 Oct; 28(4):486-499. PubMed ID: 26412324
[TBL] [Abstract][Full Text] [Related]
18. Regulation of the p53 expression profile by hnRNP K under stress conditions.
Swiatkowska A; Dutkiewicz M; Machtel P; Janecki DM; Kabacinska M; Żydowicz-Machtel P; Ciesiołka J
RNA Biol; 2020 Oct; 17(10):1402-1415. PubMed ID: 32449427
[TBL] [Abstract][Full Text] [Related]
19. SUMOylation of hnRNP-K is required for p53-mediated cell-cycle arrest in response to DNA damage.
Lee SW; Lee MH; Park JH; Kang SH; Yoo HM; Ka SH; Oh YM; Jeon YJ; Chung CH
EMBO J; 2012 Nov; 31(23):4441-52. PubMed ID: 23092970
[TBL] [Abstract][Full Text] [Related]
20. Npm1 is a haploinsufficient suppressor of myeloid and lymphoid malignancies in the mouse.
Sportoletti P; Grisendi S; Majid SM; Cheng K; Clohessy JG; Viale A; Teruya-Feldstein J; Pandolfi PP
Blood; 2008 Apr; 111(7):3859-62. PubMed ID: 18212245
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
